Joseph Barge - Spark Therapeutics Executive

Executive

Mr. Joseph W. La Barge, Esq. is Chief Legal Officer of the company. Mr. La Barge has served as our Chief Legal Officer since July 2017 and formerly served as our General Counsel from November 2013 to July 2017. Prior to joining the Company, Mr. La Barge was of counsel at Ballard Spahr LLP from April 2012 to April 2013, where he advised biotechnology companies in private and public financings, mergers and acquisitions and collaboration and licensing transactions. He also served as the Deputy General Counsel to the Kennedy Health System from April 2013 to November 2013. Mr. La Barge was the Vice President, General Counsel and Chief Compliance Officer at Tengion, Inc., in increasing roles of responsibility from November 2006 to December 2011, where he oversaw legal affairs, corporate compliance and quality assurance. Mr. La Barge serves on the board of directors of Life Sciences Pennsylvania and the National Pharmaceutical Council and also serves on the Government Affairs Committee of the American Society of Gene Cell Therapy since 2017.
Age 46
Tenure 7 years
Phone888 772-7560
Webwww.sparktx.com
La Barge holds a B.A. from Bucknell University and a J.D. from Temple University.

Spark Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.107) % which means that it has lost $0.107 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1515) %, meaning that it created substantial loss on money invested by shareholders. Spark Therapeutics' management efficiency ratios could be used to measure how well Spark Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 138.01 M in liabilities with Debt to Equity (D/E) ratio of 34.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics has a current ratio of 5.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Spark Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Spark Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Spark Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Spark to invest in growth at high rates of return. When we think about Spark Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Angelos PlataniasToro
33
Michael MitchellEagle Bulk Shipping
N/A
Michelle RoemerApogee Enterprises
N/A
Don Osmer908 Devices
58
David GuskyAvadel Pharmaceuticals PLC
39
Siobhan MawdsleyJD Sports Fashion
N/A
Eva GunnlaugsdottirAlvotech
N/A
Ioannis LazaridisToro
56
Jennifer PharmDAvadel Pharmaceuticals PLC
N/A
Curtis DoblerApogee Enterprises
59
Jason VaughnAvadel Pharmaceuticals PLC
N/A
Christina SiniscalchiAlvotech
N/A
Angie WoodsAvadel Pharmaceuticals PLC
N/A
Jerad SeurerAvadel Pharmaceuticals PLC
N/A
Giedrius ZundaAlvotech
N/A
Sandra CasacaAlvotech
N/A
Tanya ZharovAlvotech
57
Patricia BeithonApogee Enterprises
63
Mark ElrodAvadel Pharmaceuticals PLC
N/A
Jeff HuebschenApogee Enterprises
N/A
JD Esq908 Devices
57
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 368 people. Spark Therapeutics (ONCE) is traded on NASDAQ Exchange in USA and employs 368 people.

Management Performance

Spark Therapeutics Leadership Team

Elected by the shareholders, the Spark Therapeutics' board of directors comprises two types of representatives: Spark Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spark. The board's role is to monitor Spark Therapeutics' management team and ensure that shareholders' interests are well served. Spark Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spark Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Romuald Corbau, Translational Research Lead
Carol GrevePhilips, Head of Business Development and Strategy
Robert Perez, Director
Lars Ekman, Independent Director
Jennifer Wellman, Co-Founder and Head of Regulatory Strategy
Fraser Wright, Co-Founder and CTO
Morgan Molloy, Head of U.S. Commercial
Lorris Betz, Director
Joseph Barge, General Counsel and Head of Business Administration
Katherine High, President Chief Scientific Officer, Director
Elliot Sigal, Independent Director
John Furey, COO
Vincent Milano, Independent Director
Lota Zoth, Director
Rogerio Coelho, Chief Commercial Officer
Elliott Sigal, Independent Director
Guang Qu, Head of Process Development
Daniel Takefman, Head of Regulatory Affairs
Stephen Webster, CFO
Rogerio Vivaldi, Chief Commercial Officer
Diane Blumenthal, Head of Technical Operations
Jeffrey Marrazzo, CEO, Co-Founder, Director
Daniel Faga, Chief Business Officer
Anand Mehra, Independent Director
Linda Hearne, Financial Operations and Analysis Lead
Paul Gil, Regulatory CMC and Quality Assurance Lead
Charles Sigal, Independent Director
Federico Mingozzi, Chief Scientific Officer
Steven Altschuler, Chairman of the Board
Lisa Dalton, Head - Human Resources

Spark Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spark Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Spark Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Spark Therapeutics' short interest history, or implied volatility extrapolated from Spark Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Spark Therapeutics information on this page should be used as a complementary analysis to other Spark Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Spark Stock

If you are still planning to invest in Spark Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spark Therapeutics' history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
CEOs Directory
Screen CEOs from public companies around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Insider Screener
Find insiders across different sectors to evaluate their impact on performance